Our scientific legacy began with Athena Neurosciences, which was founded in 1986. Athena scientists made significant discoveries that have advanced our understanding of the biology of Alzheimer’s disease. Particularly impactful were the fundamental discoveries made in elucidating the roles amyloid, gamma secretase, and beta secretase play in the disease. These findings led to the development of a drug discovery and development organization, which generated multiple clinical candidates that have been, and continue to be, tested in Alzheimer’s disease.
These same scientists also pioneered significant scientific discoveries with cell adhesion molecules, leading to the discovery, development and commercialization of Tysabri® (natalizumab), which is FDA approved for the treatment of relapsing forms of multiple sclerosis and marketed by Biogen. Athena was acquired by Elan Corporation, plc in 1996, and its discovery and development activities were incorporated into Elan.
Prothena was established in December 2012 when it separated from Elan Corporation, plc with a substantial portion of its drug discovery platform. Our ordinary shares began trading on the Nasdaq Global Market under the symbol “PRTA” and are currently traded on the Nasdaq Global Select Market.
Prothena focuses on what we do best – developing immunotherapy approaches that interact in novel ways with proteins that are involved in amyloid or cell adhesion diseases. Today, we are drawing on our deep expertise in these areas of biology to build a pipeline of investigational compounds that could deliver innovative therapies for patients.